IL236087A0 - n–aryltriazole compounds as lpar antagonists - Google Patents
n–aryltriazole compounds as lpar antagonistsInfo
- Publication number
- IL236087A0 IL236087A0 IL236087A IL23608714A IL236087A0 IL 236087 A0 IL236087 A0 IL 236087A0 IL 236087 A IL236087 A IL 236087A IL 23608714 A IL23608714 A IL 23608714A IL 236087 A0 IL236087 A0 IL 236087A0
- Authority
- IL
- Israel
- Prior art keywords
- aryltriazole
- compounds
- lpar antagonists
- lpar
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661953P | 2012-06-20 | 2012-06-20 | |
| PCT/EP2013/062463 WO2013189865A1 (en) | 2012-06-20 | 2013-06-17 | N-aryltriazole compounds as lpar antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL236087A0 true IL236087A0 (en) | 2015-02-01 |
Family
ID=48628669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL236087A IL236087A0 (en) | 2012-06-20 | 2014-12-04 | n–aryltriazole compounds as lpar antagonists |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20150133512A1 (index.php) |
| EP (1) | EP2864301A1 (index.php) |
| JP (1) | JP2015520203A (index.php) |
| KR (1) | KR20150011389A (index.php) |
| CN (1) | CN104395299A (index.php) |
| AU (1) | AU2013279513A1 (index.php) |
| BR (1) | BR112014030674A2 (index.php) |
| CA (1) | CA2869564A1 (index.php) |
| CL (1) | CL2014003241A1 (index.php) |
| CO (1) | CO7131357A2 (index.php) |
| EA (1) | EA201492281A1 (index.php) |
| HK (1) | HK1206339A1 (index.php) |
| IL (1) | IL236087A0 (index.php) |
| IN (1) | IN2014DN09352A (index.php) |
| MA (1) | MA37762B1 (index.php) |
| MX (1) | MX2014014711A (index.php) |
| PE (1) | PE20142305A1 (index.php) |
| PH (1) | PH12014502363A1 (index.php) |
| SG (1) | SG11201407228PA (index.php) |
| UA (1) | UA110310C2 (index.php) |
| WO (1) | WO2013189865A1 (index.php) |
| ZA (1) | ZA201408167B (index.php) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8975235B2 (en) | 2011-03-20 | 2015-03-10 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| WO2014113485A1 (en) * | 2013-01-15 | 2014-07-24 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| EP2988743B1 (en) | 2013-03-15 | 2020-12-09 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| UY36060A (es) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | Compuestos de azol sustituidos con amida |
| ES2824801T3 (es) | 2014-06-27 | 2021-05-13 | Ube Industries | Sal de compuesto heterocíclico sustituido con halógeno |
| WO2017055313A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| WO2017055316A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| WO2018078009A1 (en) | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives |
| WO2018078005A1 (en) | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Amido-substituted azaspiro derivatives as tankyrase inhibitors |
| WO2018087126A1 (en) | 2016-11-09 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives as inhibitors of tankyrase |
| CN107827829A (zh) * | 2017-11-07 | 2018-03-23 | 大连理工大学 | 5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑在水相及生物介质中的制备方法 |
| CN107721984A (zh) * | 2017-11-07 | 2018-02-23 | 大连理工大学 | 一种新型5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑的制备方法 |
| CN112055710B (zh) | 2017-12-19 | 2025-01-28 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸吡唑吖嗪 |
| WO2019126084A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
| MX2020005323A (es) | 2017-12-19 | 2020-08-13 | Bristol Myers Squibb Co | Triazol azinas de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa). |
| CA3085938A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azoles as lpa antagonists |
| WO2019126085A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| KR102756639B1 (ko) * | 2017-12-19 | 2025-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 이속사졸 아졸 |
| EP3728209B1 (en) | 2017-12-19 | 2025-12-24 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as lpa antagonists |
| WO2019126103A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azoles as lpa antagonists |
| CN112041302B (zh) | 2017-12-19 | 2024-11-19 | 百时美施贵宝公司 | 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸 |
| EP3728210A1 (en) | 2017-12-19 | 2020-10-28 | Bristol-Myers Squibb Company | Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| JP7427658B2 (ja) | 2018-09-18 | 2024-02-05 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロペンチル酸 |
| CN113366000A (zh) | 2018-09-18 | 2021-09-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的氧杂双环酸 |
| CN111434653A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 三氮唑类化合物及其制备方法与用途 |
| KR102775995B1 (ko) | 2019-11-15 | 2025-03-11 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| WO2021247215A1 (en) | 2020-06-03 | 2021-12-09 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240005892A (ko) | 2021-05-11 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| EP4337654A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| EP4444707A1 (en) | 2021-12-08 | 2024-10-16 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| CN115745848A (zh) * | 2022-12-07 | 2023-03-07 | 上海优合生物科技有限公司 | 一种氨基胍的加工合成工艺 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011159550A2 (en) * | 2010-06-14 | 2011-12-22 | Amidra Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist and uses thereof |
| WO2011159633A1 (en) * | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| JP2014508111A (ja) * | 2010-12-07 | 2014-04-03 | アミラ ファーマシューティカルス，インコーポレーテッド | リゾフォスファチジン酸受容体アンタゴニスト、その線維症の治療における使用 |
| US8975235B2 (en) * | 2011-03-20 | 2015-03-10 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| EP2864300A1 (en) * | 2012-06-20 | 2015-04-29 | F. Hoffmann-La Roche AG | N-alkyltriazole compounds as lpar antagonists |
-
2013
- 2013-06-17 IN IN9352DEN2014 patent/IN2014DN09352A/en unknown
- 2013-06-17 HK HK15106924.1A patent/HK1206339A1/xx unknown
- 2013-06-17 PE PE2014002213A patent/PE20142305A1/es not_active Application Discontinuation
- 2013-06-17 UA UAA201500426A patent/UA110310C2/uk unknown
- 2013-06-17 MX MX2014014711A patent/MX2014014711A/es unknown
- 2013-06-17 BR BR112014030674A patent/BR112014030674A2/pt not_active Application Discontinuation
- 2013-06-17 SG SG11201407228PA patent/SG11201407228PA/en unknown
- 2013-06-17 AU AU2013279513A patent/AU2013279513A1/en not_active Abandoned
- 2013-06-17 CA CA2869564A patent/CA2869564A1/en not_active Abandoned
- 2013-06-17 JP JP2015517705A patent/JP2015520203A/ja active Pending
- 2013-06-17 EA EA201492281A patent/EA201492281A1/ru unknown
- 2013-06-17 MA MA37762A patent/MA37762B1/fr unknown
- 2013-06-17 KR KR1020147035551A patent/KR20150011389A/ko not_active Ceased
- 2013-06-17 US US14/403,261 patent/US20150133512A1/en not_active Abandoned
- 2013-06-17 WO PCT/EP2013/062463 patent/WO2013189865A1/en not_active Ceased
- 2013-06-17 CN CN201380031806.0A patent/CN104395299A/zh active Pending
- 2013-06-17 EP EP13729332.0A patent/EP2864301A1/en not_active Withdrawn
-
2014
- 2014-10-22 PH PH12014502363A patent/PH12014502363A1/en unknown
- 2014-11-07 ZA ZA2014/08167A patent/ZA201408167B/en unknown
- 2014-11-20 CO CO14255124A patent/CO7131357A2/es unknown
- 2014-11-28 CL CL2014003241A patent/CL2014003241A1/es unknown
- 2014-12-04 IL IL236087A patent/IL236087A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA110310C2 (uk) | 2015-12-10 |
| BR112014030674A2 (pt) | 2017-06-27 |
| CA2869564A1 (en) | 2013-12-27 |
| WO2013189865A1 (en) | 2013-12-27 |
| MA37762B1 (fr) | 2018-04-30 |
| US20150133512A1 (en) | 2015-05-14 |
| SG11201407228PA (en) | 2014-12-30 |
| PH12014502363A1 (en) | 2015-01-12 |
| MX2014014711A (es) | 2015-03-04 |
| CL2014003241A1 (es) | 2015-03-20 |
| CO7131357A2 (es) | 2014-12-01 |
| EP2864301A1 (en) | 2015-04-29 |
| CN104395299A (zh) | 2015-03-04 |
| PE20142305A1 (es) | 2015-01-16 |
| EA201492281A1 (ru) | 2015-04-30 |
| KR20150011389A (ko) | 2015-01-30 |
| MA37762A1 (fr) | 2017-07-31 |
| HK1206339A1 (en) | 2016-01-08 |
| ZA201408167B (en) | 2015-12-23 |
| JP2015520203A (ja) | 2015-07-16 |
| IN2014DN09352A (index.php) | 2015-07-17 |
| AU2013279513A1 (en) | 2014-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL236087A0 (en) | n–aryltriazole compounds as lpar antagonists | |
| IL236088A0 (en) | n-Alkyltriazole compounds as lpar antagonists | |
| SG11201406274VA (en) | Novel compounds | |
| GB201207406D0 (en) | Novel compounds | |
| SG11201504737RA (en) | Novel compounds | |
| IL238800A0 (en) | new compounds | |
| GB201212871D0 (en) | Novel compounds | |
| IL236091A0 (en) | Pyrazole compounds are converted as lpar antagonists | |
| GB201209986D0 (en) | Novel compounds | |
| IL280595A (en) | new compounds | |
| GB201222711D0 (en) | Novel compounds | |
| GB201207392D0 (en) | Novel compounds | |
| GB201209670D0 (en) | Novel compounds | |
| GB201212816D0 (en) | Novel compounds | |
| GB201222419D0 (en) | Novel compounds | |
| GB201222433D0 (en) | Novel compounds | |
| GB201222435D0 (en) | Novel compounds | |
| GB201222430D0 (en) | Novel compounds | |
| GB201222393D0 (en) | Novel compounds | |
| GB201219554D0 (en) | Novel compounds | |
| GB201219472D0 (en) | Novel compounds | |
| GB201217387D0 (en) | Novel compounds | |
| GB201216551D0 (en) | Novel compounds | |
| GB201216548D0 (en) | Novel compounds | |
| GB201213023D0 (en) | Novel compounds |